JP Morgan Chase
NVNO

JP Morgan Chase’s enVVeno Medical NVNO Stock Holding History

JP Morgan Chase’s Portfolio NVNO Stock Details NVNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$59.1K Sell
5,208
-1
-0% -$11 ﹤0.01% 6359
2026
Q1 		$52.9K Hold
5,209
– – ﹤0.01% 6173
2025
Q4 		$58.5K Hold
5,209
– – ﹤0.01% 6164
2025
Q3 		$165K Hold
5,209
– – ﹤0.01% 5618
2025
Q2 		$727K Sell
5,209
-340
-6% -$40.2K ﹤0.01% 4572
2025
Q1 		$511K Sell
5,549
-2,166
-28% -$241K ﹤0.01% 4765
2024
Q4 		$816K Buy
+7,715
New +$862K ﹤0.01% 4765
2023
Q4 		– Hold
0
– -$59 – 7764
2023
Q3 		– Hold
0
– – – 6974

Other funds holding NVNO

KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM

JP Morgan Chase's NVNO Position: Q2 2026 in Review

JP Morgan Chase reduced its enVVeno Medical (NVNO) stake by 0.02% in Q2 2026, selling an estimated $11 and leaving 5,208 shares worth $59.1K. The position accounts for ﹤0.01% of the portfolio, ranked #6359.

JP Morgan Chase first reported a position in NVNO in Q4 2024 and has held it in 7 quarters since. The position peaked at $816K in Q4 2024. 17 funds tracked by Wall St. Rank hold NVNO as of Q2 2026.

  • JP Morgan Chase held 5,208 shares of enVVeno Medical worth $59.1K as of Q2 2026.
  • JP Morgan Chase sold 1 enVVeno Medical share in Q2 2026, an estimated $11.
  • enVVeno Medical made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #6359 holding.
  • JP Morgan Chase first reported a position in enVVeno Medical in Q4 2024 and has held it in 7 quarters since.
  • JP Morgan Chase's enVVeno Medical position peaked at $816K in Q4 2024.
  • 17 funds tracked by Wall St. Rank held enVVeno Medical as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.